Effects of <i>Lactobacillus reuteri</i> supplementation on the gut microbiota in extremely preterm infants in a randomized placebo-controlled trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 33763652.
- Also identified by DOI 10.1016/j.xcrm.2021.100206 and PMC identifier 7974321.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Extremely low birth weight (ELBW) infants often develop an altered gut microbiota composition, which is related to clinical complications, such as necrotizing enterocolitis and sepsis. Probiotic supplementation may reduce these complications, and modulation of the gut microbiome is a potential mechanism underlying the probiotic effectiveness. In a randomized, double-blind, placebo-controlled trial, we assessed the effect of <i>Lactobacillus reuteri</i> supplementation, from birth to post-menstrual week (PMW)36, on infant gut microbiota. We performed 16S amplicon sequencing in 558 stool samples from 132 ELBW preterm infants at 1 week, 2 weeks, 3 weeks, 4 weeks, PMW36, and 2 years. Probiotic supplementation results in increased bacterial diversity and increased <i>L. reuteri</i> abundance during the 1<sup>st</sup> month. At 1 week, probiotic supplementation also results in a lower abundance of Enterobacteriaceae and Staphylococcaceae. No effects were found at 2 years. In conclusion, probiotics may exert benefits by modulating the gut microbiota composition during the 1<sup>st</sup> month in ELBW infants.
Medical subject headings
- Dietary Supplements
- Gastrointestinal Microbiome
- Infant, Extremely Low Birth Weight
- Infant, Extremely Premature
- Limosilactobacillus reuteri
- Probiotics